

Ref: STEX/Announcement/2023-24

Date: 11.01.2024

BSE Limited  
Department of Corporate Services-Listing  
PJ Towers, Dalal Street  
Mumbai- 400001

National Stock Exchange of India Limited  
Exchange Plaza, Bandra Kurla Complex  
Bandra (E) Mumbai- 400051

Scrip Code- 539148

Symbol- SHIVALIK

**Subject: Appointment of Senior Management Personnel – Dr. Vinod Kumar Singh as Vice President in R&D Centre, Bhiwadi**

Dear Sir/ Ma'am,

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we wish to inform you that Dr. Vinod Kumar Singh has been appointed as Vice President in R&D Centre, Bhiwadi w.e.f. January 11, 2024.

We enclose herewith brief details of the aforesaid appointment as prescribed under Listing Regulations read with SEBI circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 as **Annexure A**.

This is for your information and records.

Thanking you,  
Yours faithfully,  
**For Shivalik Rasayan Limited**

**Parul Choudhary**  
**Company Secretary & Compliance Officer**  
**ACS-34854**

### Annexure-A

Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Circular SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated 13th July, 2023.

Sr. No.	Particulars	Details
1.	Name	Dr. Vinod Kumar Singh
2.	Reason for change viz. appointment, <del>resignation,</del> removal, death or otherwise;	Appointment as Vice President in R&D Centre
2.	Date of appointment / <del>cessation (as applicable)</del> & term of	January 11, 2024
3.	Brief Profile	<p>Dr. Vinod holds degree of Ph.D.- Organic Chemistry and M.Sc.-Organic Chemistry from Magadh University. He has more than 28 years of work experience with various Organizations in Research &amp; Development.</p> <p>He was previously associated with Wockhard Research Centre, Orchid Chemical and Pharmaceutical, Dabur Research Foundation, Fresenius Kabi Ltd. and Shilpa Medicare Ltd.</p> <p>He also has rich experience of product development in API, Finished Doses, CDMO, Polymer and Peptide for US, Europe and other Markets.</p>
4.	Disclosure of relationships between Directors	Not Applicable